Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: NW_Trader who wrote (1866)	12/11/1998 3:19:00 PM
From: majormember	Read Replies (1) \| Respond to of 4140

>Tried the same for BEAM, hoping to jog my memory and while I can see similar run up, Pat, While doing my due dilly on SNRS, I went into DJ Interactive library. Here's what I have for BEAM on a P/R 7/18/95: "BEAM shares have been strong recently on perception that the company is moving closer to FDA approval, said Jonathan Cohen, analyst at SmithBarney. Cohen and most other analysts expect Summit to receive an FDA "approvable" letter and full approval by the end of the year." That would also explain VISX run to $40's by year end. Both BEAM and VISX ran up in expectation, then continued up on actual approval. BTW, Jon Cohen is now an analyst at Merrill Lynch. Doesn't follow laser stocks any more, but when I read the archives, there were a bunch of other analysts following BEAM, VISX and SNRS. I'm sure SNRS is reappearing on many of their radar screens. With no real analyst coverage, SNRS will fly when a national firm begins with a "Buy" on them, IMO. Cheers, Skane